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Altered metabolism is considered a core hallmark of cancer. By monitoring in vivo
metabolites changes or characterizing the tumor microenvironment, non-invasive
imaging approaches play a fundamental role in elucidating several aspects of tumor
biology. Within the magnetic resonance imaging (MRI) modality, the chemical exchange
saturation transfer (CEST) approach has emerged as a new technique that provides high
spatial resolution and sensitivity for in vivo imaging of tumor metabolism and acidosis.
This mini-review describes CEST-based methods to non-invasively investigate tumor
metabolism and important metabolites involved, such as glucose and lactate, as well
as measurement of tumor acidosis. Approaches that have been exploited to assess
response to anticancer therapies will also be reported for each specific technique.
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INTRODUCTION
Outgrowing tumor mass typically displays an abnormal and disorganized vascular network, with
poor functional vessels and extended hypoxic region (1, 2). Hypoxia is considered one of the
major driving forces of tumorigenesis through the activation of the hypoxia-inducible factor 1
(HIF-1), that directly alters the expression of genes related to cell metabolism and proliferation
(3). The induced metabolic modification markedly responds to tumor requirement for survival
and expansion. On one side, the upregulation of the transmembrane receptor GLUT-1 ensures
increased glucose avidity as a metabolic source of proliferation (4). On the other side, the metabolic
switch to the glycolytic pathway exposes tumors to the paradoxically accumulation of acidic
metabolites, as lactic acid and hydrogen ions, that results to be toxic for cancer cells. Therefore,
the upregulation of dedicated proton transporters allows the extrusion of acidic products on
the extracellular microenvironment, guarantees the maintenance of an aberrant pH gradient and
induces the adaptation and clonal expansion of the most aggressive cells able to survive in such a
hostile environment (5–7).
Considering the strategic role of metabolism on tumorigenesis, several targeting therapies
have been developed to interfere with tumor expansion, alone or in combination with standard
therapeutic treatments (8–13). Therefore, approaches for in vivo assessing the response to
treatments and for improving tumor diagnosis are strongly required. In the clinical setting,
positron-emission tomography (PET) technique is routinely exploited for measuring glucose
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uptake via 18F-fluorodeoxyglucose (FDG) injection, although
radiation exposure limits repeated longitudinal studies (14–
16). Furthermore, magnetic resonance imaging (MRI) offers
a wide panel of approaches, by combining an optimal
tissue contrast and good spatial information with acceptable
sensitivity, to quantitatively interrogate several aspects of tumor
microenvironment, including tumor metabolism and acidosis
(17–20). One of the most promising and emerging technique
for investigating tumor metabolism is the chemical exchange
saturation transfer (CEST)-MRI (21, 22). CEST-MRI allows the
detection of molecules endowed with mobile protons in chemical
exchange with water. The application of radiofrequency (RF)
pulses at specific offsets, corresponding to the absorbance peak
of the mobile protons, nullifies the magnetization of the mobile
protons, that become “saturated.” The exchange of the saturated
protons with those of water molecules results in a transfer of
reduced magnetization, hence in a decrease of the water signal,
generating a (negative) contrast that can be detected by MRI.
Consequently, many endogenous (proteins, peptides, sugars) or
exogenous molecules owing exchangeable mobile protons can be
imaged by CEST-MRI (23–25).
In this mini review, we will focus on CEST-MRI as a novel
tool for imaging several aspects of tumor metabolism in both
preclinical and clinical settings.
IMAGING MOBILE PROTEINS (AMIDE
PROTON TRANSFER: APT)
Amide proton transfer (APT) imaging is a CEST-MRI approach
that can detect the amide protons of endogenous mobile
proteins and peptides that resonate at 3.5 ppm (26). APT
imaging has been initially exploited for studies of ischemic
stroke, neurologic disorders and brain tumors (27–32). Tumors
exhibit a close relationship between unregulated proliferation
and concentrations of mobile proteins, that may accumulate as
defective products (33). Especially in high grade malignant brain
tumors, the level of peptides and mobile proteins is substantially
elevated (34). In Yan et al. the APT signal was compared
between normal brain tissue and tumor in rats implanted with
gliosarcoma. This study demonstrated that higher APT contrast
in brain tumor correlated with an increased concentration
of cytosolic proteins (35). In addition, APT imaging has
been used for tumor characterization and diagnosis of brain
tumors in patients (36–39). Furthermore, it is possible to use
this innovative technique to differentiate between malignant
gliomas and malignant lymphoma (40), to discriminate solitary
brain metastases from glioblastoma (41) and to predict genetic
mutations in gliomas, in particular the isocitrate dehydrogenase
(IDH) mutation status (42, 43). Another feature that makes
APT particularly interesting is its ability to differentiate between
treatment-induced effects and true tumor progression (44,
45), providing a unique and non-invasive MRI biomarker for
distinguishing viable malignancy from radiation necrosis and
for predicting tumor response to therapy (46). In addition to
brain tumors, APT imaging has been investigated in breast and
prostate cancer. As it was demonstrated in brain tumors, APT
imaging is able to discriminate between prostate cancer and non-
cancer tissues, reporting an increase of cell proliferation rate and
cellular density in tumor regions (47). Furthermore, variations
in the APT signal have been observed in breast tumors, likely
reporting about therapeutic effects and transformation of breast
parenchyma (48, 49). In summary, APT imaging represents a
promising biomarker for monitoring tumor progression and
response to treatment and can be easily implemented in existing
clinical scanners, despite further work is needed to remove
confounding effects (protein concentration, pH, etc.) to the
observed APT contrast (50–54).
IMAGING GLUCOSE
Tumors typically display upregulated glucose uptake and
glycolytic metabolism (55). In the clinical setting, PET imaging
with the glucose analog FDG is considered the gold standard
technique for non-invasively mapping glucose uptake and for
assessing tumor response to conventional therapy (56). However,
high maintenance costs and side effects related to radioactivity
exposure of patients strongly limit the repeated applications of
radionuclide techniques (57). Therefore, the idea of exploiting
unlabeled D-glucose as an MRI contrast agent may represent
a cheaper and potential alternative to FDG without involving
ionizing radiations. Glucose molecules own five hydroxylic
groups in fast exchange rate (500–6,000Hz) with bulk water
protons that can provide CEST contrast at 1–1.2 ppm from
the water resonance (58, 59). The feasibility of imaging glucose
uptake with the CEST-MRI technique was demonstrated in
colorectal tumor xenograft murine models, with glucose contrast
(GlucoCEST) correlated to FDG accumulation as measured by
autoradiography (60). A different GlucoCEST contrast was also
reported between two human breast tumor models characterized
by different metabolic activity (58). In addition, the dynamic
measurement of GlucoCEST contrast enhancements upon time
(Dynamic Glucose Enhanced—DGE) following glucose injection
showed increased penetration in brain tumors compared to the
contralateral regions, demonstrating interesting application for
brain tumors due to the reduced permeability of the blood
brain barrier (61). One limitation of the GlucoCEST approach
is the fast metabolism of native glucose that results in CEST
contrast disappearance. Therefore, non-metabolizable glucose
derivatives have been investigated for achieving prolonged
contrast (=detectability) inside the tumor regions. Once
phosphorylated by hexokinase enzymes, 2-Deoxy-D-glucose
(2DG) remains entrapped in tumor cells and provides CEST
contrast for long time, up to 90min post injection (62, 63).
However, the high doses required to generate enough contrast
are not feasible for toxicity issues. A more promising molecule
that has been intensively studied is the non-metabolizable 3-
O-methyl-D-glucose (3OMG), that is considered non-toxic.
Several studies tested 3OMG in different breast cancer models
and showed higher uptake and CEST contrast in the more
aggressive tumors, in according with the results obtained by
FDG-PET (64–66). Beyond 3OMG, glucosamine (GlcN) and N-
acetyl glucosamine (GlcNAc) can accumulate in tumors that
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overexpress the glucose transporters GLUT1 and GLUT2. These
molecules were exploited as CEST contrast agents in breast and
melanoma murine cancer models with different aggressiveness
showing diverse accumulation inside the tumor (67, 68).
Interesting results have been also obtained with low-calorie
sweeteners, like sucralose, that was shown to provide CEST
contrast in glioma tumor regions, and maltitol, that showed
increased enhancement in brain tumors with compromised
blood brain barrier (BBB) (69, 70).
Due to the high safety profile of glucose, its first use in
patients was reported as early as 2015 in a glioma patients
by using a high-field (7T) scanner (71). In comparison with
the conventional small molecular weight Gd-based contrast
agent, different areas of contrast enhancement were detected,
suggesting that D-glucose may highlight tumor regions with
different perfusion or permeability properties (Figures 1A,B).
In addition, GlucoCEST contrast time curves highlighted
potentially distinct biological areas of the brain tumor 10min
after D-glucose bolus infusion (Figures 1B,C). Another study
investigated the GlucoCEST approach in head and neck cancer
patients with a 3T scanner (72). Increased GlucoCEST contrast
was registered in the tumor regions compared to muscle tissue
and GlucoCEST enhancements were moderately correlated with
FDG-PET results, despite a spatial mismatch likely reflecting the
different metabolism between FDG and glucose. To improve
the sensitivity of GlucoCEST, a similar approach that exploits
the chemical exchange of mobile protons based on the Spin
Lock method (dubbed CESL or chemical exchange spin lock)
has been proposed for detecting glucose (73, 74). First results
were obtained at high fields (9.4T) with a dynamic acquisition
following glucose injection in glioma patients, demonstrating the
feasibility of this approach for monitoring glucose accumulation
in human brain tumors. Other studies showed a different glucose
uptake in tumor brain regions in comparison to normal gray
matter ones at lower magnetic fields (75), thus demonstrating its
translational application at clinical level (76).
Overall, these results suggest that GlucoCEST could represent
a valid alternative to FDG-PET for tumor diagnosis and staging,
still several limitations, including reduced detectability at low
field and origin of the glucose-based contrast arising from
different compartments need to be tackled in the next years (77).
IMAGING TUMOR ACIDOSIS
Intracellular Tumor pH Imaging
The amine and amide concentration-independent detection
(AACID) approach is a recently developed CEST contrast
mechanism that has been shown to be sensitive to intracellular
pH changes (pHi). AACID CEST technique uses the ratio of the
CEST effects generated by amide (1ω = 3.50 ppm) and amine
FIGURE 1 | GlucoCEST imaging in human glioma tumor. (A) Anatomical (T2-weighted, left) and contrast-enhanced upon Gd-injection (T1-weighted, right) MR images
in a glioma patient. (B) GlucoCEST contrast maps calculated as Area Under the Curve (AUC) showed at several time periods (0–110 s, left panel; 110–295 s, middle
panel; 0295 s, right panel) indicate progressive accumulation of glucose inside tumor. (C) Dynamic glucoCEST contrast time curves for several brain regions (anterior
cerebral artery, tumor core, lateral tumor rim, and contralateral vessel area). These curves show that glucose accumulation in lateral and medial tumor rim starts after
100 s of infusion, whereas the enhancement in the core area does not change over time. Reproduced with permission from Xu et al. (71).
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(1ω = 2.75 ppm) protons from endogenous tissue proteins,
which are predominantly from the intracellular space, for
removing the concentration dependence. As a consequence, the
measured CEST effect is only pH dependent, allowing to measure
tumor intracellular pH (pHi) (78). McVicar et al. exploited the
AACID CEST technique in a glioblastoma murine model to
detect the selective acidification and decrease of pHi following the
treatment with lonidamide, an anticancer drug that inhibits the
monocarboxylic transporters (78). Similar results were obtained
in glioblastoma murine models upon the administration of
several pH-modulators such as topiramate, dichloroacetate and
cariporide (79–82).
Another non-invasive pH-weighted imaging technique is the
amine CEST approach, in which the amine protons (resonating
at 3 ppm) of glutamine or glutamate molecules provide a pH-
dependent (but not concentration independent) CEST contrast
for mapping acidic tumor regions. Harris et al. applied this
approach in both glioma murine models and in glioblastoma
patients to detect acidic tumors and response to bevacizumab
treatment (83, 84). Although the high translational potential of
these endogenous approaches, concerns related to their capability
to distinguish between intra- and extracellular pH contribution
are still under consideration. In addition, variation of amide
protons concentrations might be responsible of confounding
effects resulting in less reliable pH estimations.
A recent approach to uncouple the contribution of
concentration and exchange rate to the measured CEST contrast
is that based on the omega-plot technique, initially developed
to assess chemical exchange rates in paramagnetic contrast
agents (85). Such approach has been improved and exploited for
diamagnetic molecules in vitro (simulating complex endogenous
systems) by simultaneous determination of labile proton ratio
and exchange rate (that is dependent on pH) (86, 87). Although
not yet demonstrated, the omega plot approach may provide
useful information for intracellular pH, but further technical
advancements are needed to translate it in vivo.
Extracellular Tumor pH Imaging
To overcome the limitations of endogenous CEST-MRI
techniques, exogenous molecules have been exploited as
extracellular tumor pH reporters for CEST-MRI applications.
In the last decade, great expectations surrounded the class of
the X-ray FDA-approved iodinated contrast media, considering
their high safety profile and translational potential (88). Due to
their hydrophilic chemical structure, iodinated agents remain
confined outside the cells and can be visualized as perfusion
agents in tumor by CEST-MRI (89, 90). Their first application as
pH CEST-MRI agents involved the use of iopamidol (Isovue R©,
Bracco Diagnostic), possessing two amide proton pools that
can be saturated at 4.2 and 5.5 ppm (91, 92). The set-up of a
ratiometric procedure allows to accurately measure extracellular
tissue pH (pHe) in the pH range of 5.5–7.9, independently of the
contrast agent concentration, with an accuracy of 0.1 units at
several magnetic fields (93–95). CEST-MRI tumor pH imaging
was combined to FDG-PET to elucidate the deregulation of
tumor metabolism in a breast cancer model (96). This work
evidenced that tumor regions with more acidic pHe show
increased FDG uptake and demonstrated in vivo, for the first
time, the relationship between tumor acidosis and high glycolytic
rate. In addition, it provided evidence of the feasibility of
measuring tumor pH heterogeneity at the clinical field of 3T
(Figures 2A,B). The combination of CEST pH-imaging and
FDG-PET was then exploited for predicting the early therapeutic
efficacy of metformin in a preclinical model of pancreatic
cancer (98). In addition, the possibility to measure tumor pHe
opened new routes for monitoring the effect of novel anticancer
treatments that can reverse the glycolytic tumor phenotype (97).
Anemone et al. showed that this approach can monitor early pH
changes in a breast murine cancer model upon the treatment
with dichloroacetate, a small compound targeting mitochondria,
and that can be exploited to detect the onset of the resistance,
hence providing useful insights about the therapeutic efficacy
(Figures 2C,D).
Another iodinated agent used for pH mapping is iopromide
(Ultravist R©, Bayer Healthcare), that has two amide pools
resonating at 4.6 and 5.6 ppm that can be exploited to measure
tumor pH within the 6.5–7.2 range (99). CEST-MRI with
iopromide revealed that breast cancer models with different
histopathological features show significant differences in pHe
values and that tumor acidosis is associated with metabolic
biomarkers in B-lymphoma xenografts (100, 101). In addition,
a comparative study between iopromide and iopamidol showed
that although these agents measured similar pH values in vivo,
iopamidol reveals more accurate pH measurement (102).
One of the main advantages of this class of agents relies
in their very high safety profile for administration in patients.
Consequently, CEST-MRI pH imaging with iopamidol was
initially translated for measuring kidney and bladder pH in
healthy volunteers (103–105). Later on, the capability to provide
accurate tumor pH maps was demonstrated with iopamidol in
both breast and ovarian cancer patients showing acidic tumor
pH values (106). These preliminary results pointed out that
efficient translation still requires optimization of several aspects,
including acquisition protocol and data analysis to further
evaluate the diagnostic and therapeutic utility of tumor pH
mapping in the clinical setting. To this purpose, different studies
aimed to optimize RF irradiation, reduce respiration artifacts
and enlarge the body coverage acquisition have been performed
(107–109). In addition, new ratiometric approaches have been
formulated to extend the use of iodinated agents even with
a single resonating protons for pH measurements (110, 111).
Promising results have been obtained with iobitridol (Xenetix R©,
Guerbet), showing accurate pH measurement in murine tumors
once irradiated with different power levels (112).
PARACEST pH-responsive agents are characterized by a large
chemical shift of the mobile protons from the water peak that
should improve their detectability in comparison to DIACEST
molecules, as iodinated agents or glucose (23, 113). The Yb-
HPDO3A contrast agent has been exploited for measuring tumor
pHe in both melanoma and in glioma murine models (114,
115). Interestingly, in the melanoma model changes in tumor
pHe were observed and correlated with the tumor progression
stage. Similar approaches based on other PARACEST agents
allowed to measure tumor pHe in rat brain tumor models,
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FIGURE 2 | MRI-CEST tumor pH imaging upon iopamidol injection in murine tumors. (A) CEST-MRI pHe maps of a breast cancer tumor overlaid on anatomical MRI
image upon iopamidol injection (left) and FDG-PET image overlaid on CT image (middle) upon FDG injection in the same mouse. The tumor on the right side shows
lower pHe values in the MRI-CEST pHe map corresponding to higher FDG uptake in the PET image. (B) Correlation plot between FDG-PET uptake and tumor pHe
values shows a significant inverse correlation between FDG uptake (% ID/g) and tumor pH values. Reproduced with permission from Longo et al. (96). (C)
Representative CEST-MRI tumor pHe maps overimposed on anatomical reference images before, 3 and 15 days after treatment with dichloroacetate for treated and
untreated mice. Images show increased number of less acidic pixel in treated tumors upon dichloracetate therapy in comparison to control mates. (D) Bar graphs
show a significant reduction in tumor acidosis after 3 days of treatment in treated tumors compared to untreated mates, whereas a restoration of tumor acidosis, likely
reflecting the onset of tumor resistance is reported after 15 days of treatment (*P < 0.05, Student’s t test). Reproduced with permission from Anemone et al. (97).
although direct injection of the contrast agent in the tumor
and renal ligation were needed to maintain high concentrations
of the agent for measuring pH (116–118). Currently, the high
saturation power needed to generate enough CEST contrast
limits a wider applicability of these pH responsive PARACEST
agents, howevermolecules with optimal exchange rates have been
recently proposed (119).
IMAGING LACTATE
The preferential ATP production via glycolysis of glucose to
lactate leads to high lactate levels that some cancer cells can even
exploit as a metabolic fuel (120–122). Conventionally, lactate can
be observed and quantified byMagnetic Resonance Spectroscopy
(MRS) or by the recently developed hyperpolarization technique
(123–129). However, these methods are limited by low spatial
resolution and long acquisition times. The chemical shift of
the hydroxylic proton of the lactate is very close to the water
signal and renders quite difficult to directly detect lactate in
vivo by CEST imaging. However, correlation of the signal
arising from lactate between CEST and MR spectroscopy has
been performed in a lymphoma murine tumor upon lactate
infusion (130) or in a mitochondrial disease model (131). Other
approaches exploited lactate-responsive PARACEST contrast
agents for taking advantage of the larger chemical shift difference
of these molecules and the CEST contrast dependence with
lactate concentration (132, 133). Zhang et al. (134) demonstrated
the feasibility of this approach bymeasuring lactate excreted from
lung cancer cells in tissue culture.
CONCLUSION AND FUTURE
PERSPECTIVES
In summary, CEST-MRI imaging is a fast-expanding field
with enormous potential to assess several aspects of tumor
metabolism. Moreover, since tumor acidosis is a general feature
in all tumors, imaging tumor pH might become a powerful and
wide tool for oncological imaging at both preclinical and clinical
level. First studies in patients demonstrated the feasibility of these
novel imaging approaches for imaging human tumors. Further
improvements in fast acquisition sequences, post-processing and
standardization set-up are mandatory for the widespread use
of CEST-MRI in the clinical settings. Despite the fundamental
insights that imaging tumor acidosis with iopamidol can provide,
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additional studies are needed to validate it in comparison
to established clinical approaches and to demonstrate that it
can be exploited for monitoring treatment response to (novel)
anticancer therapies.
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